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Tuberculosis (TB) remains a major health problem within the Community of Portuguese Language Speaking
Countries (CPLP). Despite the marked variation in TB incidence across its member-states and continued human
migratory ﬂux between countries, a considerable gap in the knowledge on the Mycobacterium tuberculosis po-
pulation structure and strain circulation between the countries still exists. To address this, we have assembled
and analysed the largest CPLP M. tuberculosis molecular and drug susceptibility dataset, comprised by a total of
1447 clinical isolates, including 423 multidrug-resistant isolates, from ﬁve CPLP countries. The data herein
presented reinforces Latin American and Mediterranean (LAM) strains as the hallmark of M. tuberculosis popu-
lational structure in the CPLP coupled with country-speciﬁc diﬀerential prevalence of minor clades. Moreover,
using high-resolution typing by 24-loci MIRU-VNTR, six cross-border genetic clusters were detected, thus sup-
porting recent clonal expansion across the Lusophone space.
To make this data available to the scientiﬁc community and public health authorities we developed CPLP-TB
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(available at http://cplp-tb.ﬀ.ulisboa.pt), an online database coupled with web-based tools for exploratory data
analysis. As a public health tool, it is expected to contribute to improved knowledge on the M. tuberculosis
population structure and strain circulation within the CPLP, thus supporting the risk assessment of strain-speciﬁc
trends.
1. Introduction
Tuberculosis (TB) is a devastating disease and a major public health
issue, particularly among developing countries. The World Health
Organization (WHO) declared TB as a global emergency in 1993 (World
Health Organization, 1994). In 1997, new TB cases were estimated to
ascend to approximately 8 million new cases per year and TB alone was
responsible for 1.9 million deaths (Dye et al., 1999). Almost two dec-
ades later, the WHO estimates a total of 10.4 million new incident cases
and 1.79 million deaths due to TB in 2015 (World Health Organization,
2016). The increasing trend in TB incidence shown by some countries
and the fact that some of these had a larger incidence level than that
previously recognized, have contributed to the massive number of TB
cases we face today (World Health Organization, 2016).
The Community of Portuguese Speaking Countries (CPLP - https://
www.cplp.org) comprises of nine member-states sharing a common
trait – Lusophony (i.e., Portuguese-spoke language). Together, the
member states account for 10,742,000 Km2 (7.2%) of the world's land
area and contain around 258,466,109 habitants (approx. 3.5% of the
human population). These countries accounted for 348,600 (3.4%) of
the new TB cases in 2015 and, together, they show an average incidence
rate of 87.5 new cases per 100,000 habitants (World Health
Organization, 2016). This high incidence rate is not uniform across all
member-states, ranging from 23 (Portugal) to 551 (Mozambique) new
cases per 100,000 habitants. Noteworthy, three of these countries
(Angola, Brazil and Mozambique) are within the WHO's Top 30 High-
Burden countries for TB (World Health Organization, 2016).
Mycobacterium tuberculosis, the etiological agent of TB, has shown a
highly clonal population structure but even with the present state-of-
the-art molecular ﬁngerprinting methods or Whole Genome
Sequencing, we still miss some of the links in these transmission chains
and occasionally we fail to understand how M. tuberculosis is trans-
mitted in the community (van Soolingen, 2014; Walker et al., 2013).
Still, the wide application of CRISPR-based spoligotyping, along
with other genetic markers such as IS6110, IS1081 and VNTR loci for
isolate ﬁngerprinting has enabled the delineation of broader but dis-
tinct genetic lineages and their phylogeographical association and,
lineages such as Latin American and Mediterranean (LAM) or the East
African-Indian (EAI) were subsequently assigned characteristic spoli-
gotyping proﬁles (Sola et al., 2001). However, spoligotyping inter-
rogates speciﬁc spacer sequences within the Direct Repeat (DR) locus
which evolves unidirectionally by independent loss of single spacers or
through the deletion of contiguous repeats and spacers (Groenen et al.,
1993). This unidirectional and bimodal mode of evolution may be
diﬃcult to interpret, model and, foremost, can lead to homoplasy which
can encompass a non-negligible eﬀect on strain clustering by spoligo-
typing alone (Comas et al., 2009; Reyes et al., 2012). In this sense,
VNTR-based typing emerged as a genotyping method that is less prone
to convergence by relying on the analysis of interspersed multi-allelic
loci (Supply et al., 2006). Despite this, some of the spoligotyping main
lineages or families were later conﬁrmed and deﬁned using new mo-
lecular markers such as the SNP barcode proposed by Coll et al. (2014).
The prevalence of these lineages and clades at country level has gra-
dually been made available through databases such as SITVITWEB or
MIRU-VNTRplus, enabling the study of the M. tuberculosis population
structure across diﬀerent countries (Couvin and Rastogi, 2015; Demay
et al., 2012; Weniger et al., 2010).
In the CPLP countries the body of knowledge available in the lit-
erature and databases has revealed that the M. tuberculosis populational
structure contains a high predominance of LAM strains (Demay et al.,
2012; Groenheit et al., 2011; Mokrousov et al., 2016; Perdigao et al.,
2017; Saifodine et al., 2014; Viegas et al., 2010). However, an intense
ﬂow of people has historically existed between these countries and does
still presently occur (http://migrationsmap.net). For this reason, addi-
tional tools developed for these speciﬁc countries are necessary to ra-
pidly disseminate molecular epidemiological data and enable a higher
resolution analysis of TB transmission.
The prevalence of drug resistance is highly variable across diﬀerent
CPLP member states. According to the WHO, rifampicin (RIF) resistant
and multidrug resistant (MDR) TB, i.e. resistance to at least isoniazid
(INH) and RIF, which is associated with poorer treatment outcome and
mortality, may have ascended to 14,292 cases across the CPLP in 2015
(World Health Organization, 2016). Moreover, there is mounting evi-
dence that the distribution of drug resistance is associated with speciﬁc
phylogenetic clades and that speciﬁc within-country settings are asso-
ciated with higher drug resistant TB rates than those currently esti-
mated (Perdigao et al., 2017; Perdigao et al., 2010). The ability to track
clones associated with such phylogenetic clades is therefore of the ut-
most importance in preventing the emergence of drug-resistant strains,
including MDR- and XDR-TB, throughout the diﬀerent countries.
Here, we combined diﬀerent datasets from several member-states to
provide a new framework for tracing speciﬁc M. tuberculosis strains
across the Lusophone space and developed CPLP-TB, an online database
aimed at disseminating molecular epidemiological data.
2. Methods
2.1. Clinical isolates and datasets
Five distinct datasets (Angola, n= 89; Brazil, n= 964; Guinea-
Bissau, n= 13; Mozambique, n=14; and, Portugal, n= 367) totalling
1447 M. tuberculosis clinical isolates (all of which recovered from dif-
ferent patients) were studied:
• Angolan dataset (n= 89): comprised by clinical isolates recovered
from sputum samples obtained between March to June 2015 from
the Hospital of Divina Providência in Luanda which, serves an es-
timated population of 990,892 inhabitants. This sample comprises
approximately 18% of this hospital's yearly diagnosed cases;
• Brazil dataset (n= 964): this dataset is comprised by isolates from
Rio Grande recovered at University Federal do Rio Grande (n= 624,
2006–2016) covering 30% of all TB cases and, 100% of the TB/HIV
cases in the city of Rio Grande in this period; and, by MDR-TB/INH-
resistant isolates from Porto Alegre and surrounding metropolitan
area obtained from the LACEN - Rio Grande do Sul (n= 340,
2010–2014), estimated to cover 50% of such cases in the same
period;
• Guinea-Bissau (n=13): includes all MDR-TB strains collected in
Bissau, Guinea-Bissau, at Hospital Raoul Follereau, during the
period from May to December 2012;
• Mozambique (n=14): this dataset includes DNA obtained from
isolates recovered at Laboratório Nacional de Referência da
Tuberculose from patients diagnosed at Hospital Central de Maputo
between January to March 2012;
• Portugal (n=367): includes isolates recovered from nine distinct
laboratories and hospitals across Lisbon Health Region between
1995 and 2016. Most cases (n=349) were obtained between 2007
and 2015 and include 129 MDR-TB cases that are estimated to
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correspond to 65% of all the MDR-TB cases reported nationwide for
the same period.
The inclusion criterion for this study was the availability of geno-
typic data: MIRU-VNTR (either 15 or 24 loci) and/or spoligotyping. All
methods were performed in accordance with the relevant guidelines
and regulations.
2.2. Drug susceptibility testing (DST)
DST, when available, was carried out for ﬁrst-line drugs using the
standardized procedure of the BACTEC™ MGIT™ 960 System (Becton
Dickinson Diagnostic Systems, Sparks, MD, USA), except for a subset
(n=283/964) of the isolates from Brazil for which phenotypic drug
susceptibility was assessed by the resazurin microtiter assay (REMA)
(Palomino et al., 2002). Phenotypic data on pyrazinamide (PZA) sus-
ceptibility was only available for 90 out of the 713 isolates tested for
ﬁrst-line drug susceptibility in Brazil since PZA susceptibility is not
routinely performed in this country. For this same reason, clinical iso-
lates recovered in Portugal before 2000 also lack data on PZA sus-
ceptibility.
DST data for second-line drugs (SLDs) was available for 48, 9 and 98
MDR-TB clinical isolates from Brazil, Guinea-Bissau and Portugal, re-
spectively. For this study, only phenotypic susceptibility data for
ﬂuoroquinolones (FQ; oﬂoxacin, ciproﬂoxacin or moxiﬂoxacin) and
second-line injectable drugs (SLIDs; kanamycin, amikacin or capreo-
mycin) were considered.
Clinical isolates susceptible to all ﬁrst-line drugs tested were clas-
siﬁed as pan-susceptible isolates; resistance to at least isoniazid (INH)
and rifampicin (RIF) was classiﬁed as MDR; any resistance pattern in-
cluding resistance to one or more antituberculous drugs other than INH
and RIF combined were classiﬁed as non-MDR; MDR-TB isolates
showing cumulative resistance with any FQ and a second-line injectable
drug were classiﬁed as extensively drug resistant (XDR). MDR-TB iso-
lates lacking data on SLD susceptibility were, nonetheless, classiﬁed as
MDR-TB.
2.3. MIRU-VNTR typing
Fifteen- or 24-loci MIRU-VNTR typing was carried out using the
single or multiplex ampliﬁcation procedure described by Supply et al.
(2006). Amplicon size determination was carried out by agarose gel
electrophoresis or capillary electrophoresis as described previously
(Supply, 2005). Allelic diversity (h) for each locus was calculated using
the equation h=1− Σxi2, where xi is the relative frequency of the i th
allele (Sun et al., 2004). A MIRU-VNTR dendrogram was constructed
using R and ape package for phylogenetic analysis (Paradis et al.,
2004). A MIRU-VNTR cluster was deﬁned as a group of more than one
isolate sharing indistinguishable MIRU-VNTR proﬁles and a cross-
border cluster deﬁned as a MIRU-VNTR cluster where all clinical iso-
lates do not originate from the same country. Isolates showing two or
more loci with dual allele proﬁles (assessed by dual peak or dual
banding upon capillary/gel electrophoresis) were removed from the
study.
2.4. Spoligotyping
Spoligotyping was performed by a single-tube multiplex PCR am-
pliﬁcation of 43 spacer regions of the direct repeat (DR) locus using
oligonucleotide primers DRa (5′-Biotin-GGTTTTGGGTCTGACGAC-3′)
and DRb (5′-CCGAGAGGGGACGAAAC-3′) and 20 ng of genomic DNA.
Amplicons were reverse hybridized on a membrane with amino-linked
immobilized probes for each spacer as described previously by
Kamerbeek et al. (1997). Detection was performed using the ECL®
Chemiluminescence Detection System (GE Healthcare®, Cleveland, OH,
USA) as per the manufacturer's instructions.
Spoligotyping proﬁles were assigned to lineage, clade and shared
international type (SIT) using the rules described in SITVITWEB and
SITVIT2 international databases (Couvin and Rastogi, 2015; Demay
et al., 2012).
SIT assignment was carried out by entering the data in an updated
proprietary version of SITVIT (SITVITEXTEND, housed at Institut
Pasteur de la Guadeloupe). Minimum Spanning Trees (MST) were
drawn using MLVA Compare software (Genoscreen, Lille, France and
Ridom Bioinformatics, Münster, Germany).
2.5. Database development
CPLP-TB user interface was developed and implemented with Shiny
by Rstudio (http://shiny.rstudio.com). Data processing, map and tree
plots were implemented using the following R packages: ggplot2, ape,
plotGoogleMaps, ggtree and Cairo (Paradis et al., 2004). Interactive
choropleth mapping of clinical isolates by country of origin was carried
out using Google Maps API. Source and data processing code is avail-
able upon request from the corresponding author.
The web application contains a left-sided panel that enables the user
to apply ﬁlters (e.g. year interval, country of origin, drug resistance,
SIT/Clade, MIRU-VNTR cluster, etc) to the data being displayed on a
main panel. This main panel is automatically updated according to the
ﬁltering criteria set on the left panel, and features diﬀerent page tabs: a
data table that lists all isolates' records deposited in this database along
with phenotypic and genotypic data, allowing the user to browse
through the diﬀerent clinical isolates and apply additional ﬁlters to the
data table; diﬀerent plots that summarize data contained in the data-
base, e.g., barplots showing the distribution per year, resistance type or
SITs/clade; an interactive Google Maps API-based choropleth map
showing the distribution of isolates per country; MIRU-VNTR and
spoligotyping dendrograms; and, a genome-wide SNP-based phyloge-
netic tree containing the isolates present in the database that have al-
ready been subjected to Whole Genome Sequencing, annotated with the
diﬀerent SNP barcode sub-lineages previously identiﬁed by Coll et al.
(2014). In its ﬁrst and current release, CPLP-TB accommodates the
datasets described in the present study.
2.6. Statistical analysis
All statistical analyses were conducted using the IBM© SPSS©
Statistics v.21 (IBM Corporation, Armonk, NY, USA) or R (R Foundation
for Statistical Computing, Vienna, Austria).
3. Results and discussion
3.1. Dataset description: country of origin, isolation years and drug
resistance
Through a collaborative eﬀort, the largest of this kind aimed at
cataloguing the genetic diversity of M. tuberculosis across CPLP coun-
tries, this study brought together ﬁve distinct datasets comprised by M.
tuberculosis clinical isolates recovered in ﬁve distinct CPLP countries:
Angola (n=89); Brazil (n= 964); Guinea-Bissau (n=13);
Mozambique (n=14); and, Portugal (n=367). These clinical isolates
comprise a convenience sample collected from several laboratories and
hospital units (see Methods for further details) between 1995 and 2016
(Table 1). The distribution per year of these clinical isolates and the
number of drug resistant isolates to ﬁrst-line drugs is summarized in
Table 1. Brieﬂy, from a total 1447 clinical isolates included in this
study, 1182 (81.7%) were subjected to ﬁrst-line DST, from which 423
(35.8%) were classed as MDR-TB isolates. Despite the availability of FQ
and SLID DST data for 48 and 9 MDR-TB isolates from Brazil and
Guinea-Bissau, respectively, XDR-TB isolates were only detected in the
Portuguese dataset (n= 40) comprising 40.8% of the MDR-TB isolates
tested for susceptibility to FQ and SLID in this country. This rate agrees
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with previous data on this setting and is the cause of major concern
regarding ongoing extension of drug resistance to third-line drugs
(Perdigao et al., 2013; Perdigao et al., 2016). In the Brazil dataset, no
XDR-TB isolate was detected which, is not unexpected given the low
number of isolates with data for second-line drug susceptibility testing
(n= 48) and is in line with the low rate of XDR-TB estimated by the
WHO for Brazil (5.9%) (World Health Organization, 2016).
The convenience-nature of the sampling constitutes a limitation to
this study, but this is not an untypical design in a pathogen genetic
setting, where clinically and epidemiological relevant isolates are
characterized. Isolate inclusion based on availability of genotypic data
is a common criterion due to their association with drug resistance. The
prevalence of drug resistant strains does not necessarily reﬂect their
local prevalence, except in the Angolan dataset, which was system-
atically collected over a deﬁned period to assess drug resistance pre-
valence in a speciﬁc study population (Perdigao et al., 2017). None-
theless, the datasets herein combined comprise the basis for the ﬁrst
attempt to investigate the global molecular epidemiology within the
CPLP, enabling the investigation of possible links, and, provide a con-
siderable progress to an expanding body of knowledge concerning M.
tuberculosis genetic diversity in its member-states. It is, however, ne-
cessary to bear in mind potential bias in low sampled settings such as
Mozambique and Guinea-Bissau and, furthermore, we stress the im-
portance of future prospective studies that can play a key role in ob-
taining increasingly robust estimates on drug resistance in countries
that do not carry out DST on a routine basis and, evaluate the impact of
control programme interventions. Such studies should ideally en-
compass a uniform DST methodology, both country-wide and CPLP-
wide, based on rapid nonradiometric liquid culture (Bemer et al.,
2002). Currently, lack of routine culture-based DST poses an enormous
limitation to this study and such future studies. Country policy on
culture-based DST is not uniform across the CPLP where: Portugal
performs it routinely for all culture-positive cases; CPLP African coun-
tries due to the high number of cases and lack of adequate laboratory
support do not perform it routinely; and, in Brazil, country policy
mandates routine culture-based DST to be carried out mainly for HIV
co-infection cases, relapse, retreatment or treatment default cases.
Herein, a subset of the samples obtained from Brazil were subjected to
DST using REMA which should also be considered when analysing the
data, albeit the good correlation between both methods on the eva-
luation of susceptibility to ﬁrst-line drugs (Coban et al., 2014; Palomino
et al., 2002).
3.2. Assessing M. tuberculosis population structure diversiﬁcation through
spoligotyping
To uncover the M. tuberculosis population structure in a country-
wise manner, the combined dataset included spoligotyping data for
1239 clinical isolates, which corresponded to: 89 (7.2%) isolates from
Angola; 760 (61.3%) from Brazil; 13 (1.0%) from Guinea-Bissau; 14
(1.1%) from Mozambique; and, 363 (29.3%) from Portugal. A total of
248 spoligotyping proﬁles were obtained, which corresponded to 164
SITs and 62 proﬁles classiﬁed as Orphan (Supplementary Tables S1 and
S2). Additionally, 22 new SITs were identiﬁed upon data submission to
SITVITEXTEND (SIT4139–4160). Overall, the most prevalent SITs
found were SITs 20/LAM1 (n=157; 12.7%), 42/LAM9 (n= 94/7.6%)
and 53/T1 (n=92; 7.4%) while the most prevalent clades encountered
were the T1 (n=211; 17.0%), LAM1 (n= 205; 16.5%), LAM9
(n= 141; 11.4%), H1 (n=90; 7.3%), H3 (n=83; 6.7%) and LAM4
(n= 67; 5.4%).
Comparing the distribution of the spoligotyping proﬁles by country,
only the Portuguese dataset included isolates from all major M. tu-
berculosis lineages (Table 2). Remarkably, no Beijing strain was en-
countered on the Brazilian dataset despite its the large sample size. This
is most likely correlated with the low prevalence of Beijing strains in
this country as only 10 (0.3%) out of 2992 strains deposited inTa
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SITVITWEB belonged to the Beijing clade (Demay et al., 2012). The
prevalence in Rio Grande do Sul state, from where the Brazilian dataset
originates, is most likely even lower given the fact no Beijing isolate
was identiﬁed in this study (Table 2). Previously reported data in the
literature support this low prevalence of Beijing strains among the M.
tuberculosis populational structure in Brazil (< 1%) and, similarly,
across South American countries such as Argentina, Paraguay and Chile
(Balcells et al., 2015; Demay et al., 2012; Gomes et al., 2012). An ex-
ception is Peru that has reported a prevalence of Beijing strains ranging
between 5.5 and 9.15% (7.4% on SITVITWEB) (Caceres et al., 2014;
Demay et al., 2012; Sheen et al., 2013). In contrast, in Guinea-Bissau,
despite the reduced sample size, 8 (61.5%) out of 13 isolates belonged
to Beijing clade. Although this fact is not surprising since Beijing iso-
lates were previously detected in this country, the number of isolates
retrieved from such a low-sized sample suggests that Beijing isolates
may have been introduced more recently and appear to be emerging in
this setting, as previously suggested (Rabna et al., 2015). Such emer-
gence of Beijing strains beyond what can be considered its normal
Table 2
– Isolates characterized by spoligotyping, number of obtained SITs and number of isolates classiﬁed in the main spoligotyping lineages per dataset.
Country No. of isolates No. of SITs No. of orphan proﬁles Spoligotyping main lineages - no. of isolates (%)
Beijing CAS EAI H LAM S T X
Angola 89 25 8 0 (0) 0 (0) 0 (0) 1 (1.1) 55 (61.8) 0 (0) 31 (34.8) 0 (0)
Brazil 760 90 81 0 (0) 0 (0) 1 (0.1) 152 (20) 326 (42.9) 8 (1.1) 185 (24.3) 13 (1.7)
Guinea-Bissau 13 5 0 8 (61.5) 0 (0) 0 (0) 0 (0) 2 (15.4) 0 (0) 0 (0) 0 (0)
Mozambique 14 6 4 0 (0) 0 (0) 2 (14.3) 3 (21.4) 2 (14.3) 2 (14.3) 2 (14.3) 0 (0)
Portugal 363 77 13 26 (7.2) 4 (1.1) 4 (1.1) 18 (5) 226 (62.3) 3 (0.8) 42 (11.6) 17 (4.7)
Fig. 1. Minimum Spanning Tree (MST) based on all available spoligotyping patterns in this study (n=1239 isolates). Node coloring is shown in function of lineages
and thickness and/or shape of branches (continuous, dashed, dotted, black or gray) varied in function of spacer changes between patterns. The number of changes is
indicated on branches.
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phylogeographical niche may be associated and being driven by (multi)
drug resistance and/or HIV co-infection, a phenomenon previously re-
ported in other settings (Lasunskaia et al., 2010; Liu et al., 2018; Viegas
et al., 2013).
A common denominator appears to be LAM and the “ill-deﬁned” T
clade, found to be present across all datasets with diverging prevalence,
highlighting speciﬁc populational structures across all settings
(Table 2). Analysis of a minimum spanning tree based on spoligotypes
(Fig. 1) reveals that LAM lineage is particularly diverse in this study.
Interestingly, while the prevalence of LAM strains in the Angolan and
Portuguese datasets was similar, there was a diﬀerence in the dis-
tribution of the most prevalent SITs (> 5%) among LAM clades in the
Portuguese and Angolan datasets (Table 3). Angola showed a pre-
valence of SIT42/LAM9 strains that was twice the one in the Portuguese
dataset, while the latter had a higher prevalence of SIT20/LAM1
strains. Also, SIT1106/LAM4 strains were only detected in Portugal,
stressing the endemicity of this clade and its most likely origin in this
country (Supplementary Fig. S1). Although previously reported in
Brazil, the number of SIT1106/LAM4 isolates herein included from
Portugal exceeds by 1.7-fold the number of these strains present in the
SITVIT database (Table 3). Moreover, SIT1106/LAM4 have been asso-
ciated with M/XDR-TB isolates of the Q1 cluster in Portugal and its
global importance has recently been highlighted due to the potential to
extend its drug resistance proﬁle towards third-line drugs (Perdigao
et al., 2016).
Despite detected in Portugal and Brazil, EAI strains appear to be of
particular epidemiological signiﬁcance in Mozambique where, despite a
low sample size, 4 out of 14 (28.6%) strains belonged to this lineage
(Table 2). This high prevalence is likely related with the proximity to
the Indian subcontinent (Gagneux et al., 2006). In fact, the newly de-
scribed SIT4140 could be speciﬁc to Mozambique and although labelled
as an Unknown clade due to the absence of speciﬁc spacers it could
potentially belong to the EAI lineage. In Brazil, Haarlem strains (SIT45/
H1 and SIT50/H3, mostly) are also noteworthy, possibly representing
more recently introduced European strains brought by European set-
tlers of diverse origins (e.g., Italy, Poland, Germany and Russia) over
two centuries ago (Garzelli et al., 2010; Jagielski et al., 2010; Lari et al.,
2007). Still in the Brazilian dataset, the prevalence of T strains appears
to be mostly underpinned by two diﬀerent clades: SIT53/T1 and SIT65/
T1. While SIT53/T1 strains are well dispersed through CPLP countries
and was detected in all datasets except Guinea-Bissau, SIT65/T1 shows
a much more restricted distribution and is in fact more prevalent in
Brazil, with our data supporting a much higher prevalence in Rio
Grande do Sul state where we obtained a prevalence of 7.9% (Table 3).
Finally, 14 out of the 17 main SITs (prevalence≥5%) detected in each
country correlate well with the countries associated with at least 2% of
the SIT's global distribution, thus strengthening the current under-
standing of M. tuberculosis phylogeography (Table 3).
3.3. A MIRU-VNTR framework for the CPLP
Of the 999 (69.0%) isolates genotyped by MIRU-VNTR, 181, 420
and 398 isolates were genotyped by 12, 15 and 24-loci MIRU-VNTR,
respectively (Table 4). The MIRU-VNTR loci set used varied according
to practice of the laboratories participating in this study. It was not
possible to obtain data on MIRU-VNTR typing from the Mozambique
dataset.
To understand the local transmission patterns and assess strain
identity using a method with a higher discriminative power, we started
by considering all clinical isolates genotyped by 15-loci MIRU-VNTR.
The latter, can also be obtained from strains genotyped using the 24-
loci set and has shown a comparative discriminatory power when
compared with the 15-loci set. From the possible 818 MIRU-VNTR
proﬁles available, 15 were excluded due to incomplete proﬁles, ren-
dering a total of 802 15-loci MIRU-VNTR proﬁles suitable for analysis.
Upon construction of a MIRU-VNTR dendrogram, we have identiﬁed
522 unique proﬁles and 75 genetic clusters encompassing a total of 356
(44.3%) clinical isolates (Supplementary Fig. S2). The remaining 447
(55.7%) isolates were classiﬁed as non-clustered (NC) isolates.
Combining both country of origin and the genotypic proﬁle generated
by 15-loci MIRU-VNTR, 65 clusters were country-speciﬁc while the
remaining 10 clusters were deﬁned as cross-border clusters (CPLP
clusters), containing between 2 and 17 isolates each from distinct
countries. The largest CPLP cluster (CPLP-01) included 17M. tubercu-
losis isolates from three distinct countries: Angola (n=9), Brazil
(n= 6) and Portugal (n=2) (Supplementary Table S1).
However, despite the high discriminatory power (HGI=0.993),
MIRU-VNTR was not fully congruent with cluster associated SITs as 21
of 51 clusters that had two or more isolates showed mixed spoligo-
typing proﬁles (Supplementary Table S3). In nine of these, clustering
incongruences cannot be simply explained by subsequent diversiﬁca-
tion at the DR locus level, suggesting convergence of MIRU-VNTR
proﬁles.
Next, to compare with 24-loci MIRU-VNTR clustering, from the 398
isolates genotyped by this method, 17 failed to amplify at least one
locus and a dendrogram was constructed for the remaining 381 isolates:
89 from Angola, 71 from Brazil, 13 from Guinea-Bissau and 208 from
Portugal (Fig. 2, Supplementary Fig. S3). Using this method, we have
identiﬁed 33 clusters encompassing a total of 152 (40.2%) clinical
isolates (HGI= 0.986). The lower discriminatory power obtained was
mostly due to the high prevalence of MDR- and XDR-TB clones in the
Portuguese dataset and because, most of the susceptible isolates from
Brazil were genotyped by 15-loci MIRU-VNTR whereas drug resistant
isolates were more likely to have been genotyped by 24-loci MIRU-
VNTR. Nevertheless, some clusters were further resolved leading to the
deﬁnition of two additional clusters but supporting at least partial
clustering of 32 of the original 75 genetic clusters deﬁned using the 15-
loci set (Supplementary Table S4). A subset of 6 clusters deﬁned using
the 24-loci set yields further support to clonal expansion at a transna-
tional level. A MIRU-VNTR dendrogram including all isolates geno-
typed by 15 or 24-loci MIRU-VNTR is also included as Supplemental
material (Supplementary Fig. S4).
Beyond the Lusophone space, and concerning the Beijing strains
isolated from Guinea-Bissau, analysis by 24-loci allows the assignment
of three isolates to type #94-32 (MLVA MtbC15-9 scheme), also termed
as Russian/Asian clone CC1 (IS6110-RFLP-deﬁned A0-cluster) (Merker
et al., 2015; Mokrousov et al., 2008). These ﬁndings place the most
likely origin of these strains in the former Soviet Union as type #94–32
is one of the two main Beijing types in Russia and highly prevalent in
the former soviet Central Asia (Merker et al., 2015; Mokrousov et al.,
2018; Mokrousov et al., 2008; Skiba et al., 2015).
The potential epidemiological links and similar population struc-
tures between present Lusophone countries may have its roots back to
the 16th century with the historical overseas exploration period that
brought together diverse cultures across distinct continents. More spe-
ciﬁcally, the similar population structure may have its common ground
in the transatlantic trade routes and the African diaspora linking
Portugal, Brazil and probably having Central Africa, a region that
presently includes Angola, as its hub (Patarra and Fernandes, 2011). It
is estimated that until 1850, slave trade introduced about 4 million
African people in Brazil, most likely shaping the present M. tuberculosis
Table 4
Number of isolates genotyped by 12, 15 and 24-loci MIRU-VNTR.
MIRU-
VNTR set
No. of isolates (%) Total
Angola Brazil Guinea-
Bissau
Mozambique Portugal
12-loci 0 (0) 181 (100) 0 (0) 0 (0) 0 (0) 181
15-loci 0 (0) 420 (100) 0 (0) 0 (0) 0 (0) 420
24-loci 89 (22.4) 83 (20.9) 13 (3.3) 0 (0) 213 (53.5) 398
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population structure of this country since this population may have
reached up to one-third of the total population (Graham, 2002; Prado
Jr., 2012). Furthermore, the importance of this population as an in-
coming TB reservoir is well documented from archaeological specimens
(Jaeger et al., 2013; Jaeger et al., 2012). However, indistinguishable
genetic clusters probably have its origins in more recent migratory
events, diﬃcult to ascertain due to the complexity of the Lusophone
migratory system (Fig. 3), which some consider to be structured around
three main hubs: Angola, Brazil and Portugal (Baganha, 2009; Marques
and Góis, 2011). More recent periods of migration during the third, and
early fourth, quarter of the 20th century, after the independence of
Angola led to the return of approximately 500,000 settlers from former
Portuguese colonies to Portugal, mostly coming from Angola, and a
small minority to Brazil (Baganha, 2009). This mass migration might
have, as well, played a key role in shaping M. tuberculosis population
structure in recent times and underpin some of the cross-border clusters
here observed. Nevertheless, these considerations do not exclude the
ongoing migratory ﬂows that take place up to this day and that might
also explain smaller or still undetected clusters. Also, the detection of
other unusual underrepresented clades are likely associated with more
recent events leading to the introduction and emergence of these strains
or, with additional migratory systems to which each country is prone to
be inserted in given the local geographical context (Goldblatt et al.,
2014; Mokrousov, 2016; Tolentino et al., 2011).
3.4. MIRU-VNTR loci and allelic diversities
Concerning the discriminatory capability of the diﬀerent MIRU-
VNTR loci used, we calculated the allelic diversity (h) for each locus,
overall and across each country set, for the two sets of strains assessed
by 15 and 24-loci MIRU-VNTR (Fig. 4). MIRU-VNTR loci were classiﬁed
as poorly (h < 0.3), moderately (h=0.3–0.6), and highly (h > 0.6)
Fig. 2. Twenty-four loci MIRU-VNTR tree obtained for 381 isolates annotated with color-coded tip points that represent the country of origin (inner rim) and drug
resistance (outer rim). Six cross-border clusters can be observed in the present tree as well as the association of XDR-TB isolates in Portugal with two main MDR-TB
genetic clusters (Lisboa3-B and Q1).
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discriminatory. Globally, loci 2163b and 4052 showed the highest dis-
criminatory power (h=0.77 and 0.81, respectively) while loci 580 and
2687 present the lowest allelic diversity (h=0.07 and 0.05, respec-
tively). The allelic diversity scores found for this sample of isolates were
comparable to other published datasets comprised by clinical isolates of
diverse geographical origin, except for loci 580 and 2687 (Mokrousov
et al., 2004; Sola et al., 2003; Supply et al., 2006). These loci exhibited
very low allelic diversities across all datasets that strikingly contrast
with the ones obtained in the aforementioned studies. However, when
comparing with studies of a more geographically localized scope, the
allelic diversities obtained herein tend to be higher (Chen et al., 2012;
Cowan et al., 2002; Mazars et al., 2001; Mokrousov et al., 2004;
Shamputa et al., 2010; Supply et al., 2003; Wada et al., 2009).
3.5. Assigning phylogenetic deﬁned sub-lineages to LAM strains
Given the epidemiological importance of the LAM lineage in the
CPLP, we attempted to assign Spoligotyping and Region of Diﬀerence
(RD)-based LAM-sublineages to the isolates genotyped by 24-loci
MIRU-VNTR as the tree obtained for these isolates is more robust from a
phylogenetic standpoint (Supplementary Fig. 2). The resulting tree was
examined for the distribution of speciﬁc MIRU-VNTR alleles previously
proposed by Mokrousov et al. (2016) as a proxy for some LAM-sub-
lineages (Mokrousov et al., 2016).
Within the LAM lineage, isolates bearing the 802_1 allele (locus 802,
number of repeats: 1) which was proposed to correlate with RD174
sublineage were found to comprise a monophyletic branch containing
184 isolates in which all, but 1 isolate, exhibit this speciﬁc allele. This
sub-lineage harbours the most important strains from an epidemiolo-
gical standpoint, speciﬁcally: the Lisboa3-A/B (SIT20/LAM1) or Q1
(SIT1106/LAM4) clusters in Portugal; RS-04 (SIT106/LAM7) cluster in
Brazil; or, the CPLP-1 cluster that is shared at a transnational level.
Supporting this, data on the genome-wide analysis of Lisboa3 and Q1
strains have already shown the association between these clusters and
RD174/RDRIO (Perdigao et al., 2014).
Thirty-one isolates were also found to form a monophyletic branch
Fig. 3. Lusophone migratory system depicting global migratory ﬂows between the CPLP countries herein studied (orange arrows). Total migratory ﬂow is indicated
and proportionally represented by each arrow connecting these countries/regions. The percentage values indicated within parentheses represent the fraction of the
total outward migratory ﬂow from the country of origin. It is noteworthy the role played by Portugal as a central hub in this migratory system and the intense
migratory events occurring between Portugal, Angola and Brazil. Part of the African diaspora is also represented in the present map as a major mass migratory event,
taking place over four centuries, connecting the African continent with Brazil and leading to the introduction of at least 4,000,000 African slaves (yellow arrow).
Another more recent and historical mass migratory event, with potential impact on the PortugueseM. tuberculosis populational structure in Portugal, occurred during
the 70's as the result of the return of Portuguese settlers following the end of the Portuguese Colonial War (green arrow). Source: Trends in International Migrant
Stock: Migrants by Destination and Origin. United Nations, Department of Economic and Social Aﬀairs, 2015; ﬁgure generated using Microsoft® PowerPoint® 2016
[Version 1707] and Microsoft® Excel® 2016 (Version 1707), incl. Microsoft® Power Map 3D Data Visualization Tool (https://products.oﬃce.com/en-us/business/
oﬃce). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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containing the 154_1 allele as a marker for the RD115 sublineage. This
branch included, among others, the “pinnipedii-like” strains SIT863/
PINI2 which has been shown by some of us to in fact belong to the LAM
lineage (Dalla Costa et al., 2015). Interestingly, the SIT863/PINI2
strains underwent diversiﬁcation at locus 154 (154_2). The phyloge-
netic positioning of SIT863/PINI2 in the RD115-sublineage is congruent
with previous data on its SNP barcode lineage (4.3.3) as a RD115 sub-
lineage branch (Coll et al., 2014; Dalla Costa et al., 2015). Nevertheless,
some phylogenetic incongruences were noted as other unrelated strains,
e.g., Beijing or T1, were included in this branch, thus exemplifying the
problem of MIRU-VNTR convergence.
The “SIT33-sublineage” was also identiﬁable among LAM strains:
characterized by MIRU-VNTR alleles 2401_2 and 3171_1, a branch was
identiﬁed as associated with these alleles. This speciﬁc branch was
composed by 18 isolates of which 4 belonged to SIT33/LAM3 while
four exhibited putative SIT33-derived spoligotyping proﬁles. Three
isolates were, nevertheless, characterized by spoligotyping proﬁles
apparently unrelated to SIT33. Furthermore, MDR-TB RS-04 cluster
(SIT106/LAM7) was found to belong to this sub-lineage highlighting its
importance in Brazil.
Additionally, we also examined the tree for allele 2059_1 which is
proposed to be associated with the SIT388-sublineage, which was not
found for any LAM isolate except for a branch within the RD115 sub-
lineage. This marker has been reported as the least robust concerning its
Positive Predictive Value but interestingly, this putative sub-branch
comprised ﬁve isolates, aside an isolate with the 2059_2 allele, that
included the SIT863/PINI2 isolates as the only strains bearing a proﬁle
compatible with descent from SIT388. However, SIT388-sublineage is
proposed by Mokrousov et al. (2016) to be derived directly from SIT42/
LAM9/RD115 strains and therefore constitute a Japan-endemic parallel
branch to the RD115 sublineage consistent with its association with
SNP barcode 4.3.1 (Coll et al., 2014; Mokrousov et al., 2016).
3.6. Drug resistance association with MIRU-VNTR clusters and
spoligotyping clades
We have further analysed the distribution of drug resistant isolates
across the MIRU-VNTR dendrograms and SITs/clades. Intersecting
phenotypic drug resistance with the previously deﬁned 24-loci MIRU-
VNTR generated clusters, 30 where associated with drug resistant
strains. From these, 22 and 4 comprised MDR-TB and XDR-TB strains,
respectively. Looking further into the association of these clusters with
drug resistance, it is noteworthy the statistically signiﬁcant higher
proportion of XDR-TB within Lisboa3, Q1 and Q1-derived PT-07
(SIT1106/LAM4) clusters in comparison to MDR-TB and/or strains
exhibiting any type of drug resistance other than MDR/XDR in the same
clusters (z-test, p < 0.05). In Lisboa3 cluster this association was also
signiﬁcant when comparing the higher proportion of MDR-TB strains
with the proportion of strains exhibiting any type of drug resistance (z-
test, p= 0.02).
Finally, the proportion of non-clustered pan-susceptible isolates was
signiﬁcantly higher than non-clustered isolates exhibiting MDR, XDR or
any type of drug resistance (z-test, p < 0.01).
When analysing the dendrogram generated using 15-loci set, which
enables the use of a larger subset of the isolates herein analysed, the
statistical association is further extended to the clusters PT-03, showing
a higher proportion of isolates with any type of drug resistance other
than MDR/XDR relative to susceptible isolates (z-test, p= 0.019); and,
cluster RS-05, showing a higher proportion of MDR-TB than susceptible
isolates (z-test, p= 0.021).
This data provides further support to the epidemiological im-
portance of Lisboa3 and Q1 phylogenetic clades that, despite the in-
clusion of other datasets from diverse countries, maintain a high degree
of endemicity in Portugal and, calls for the adoption of speciﬁc control
measures (e.g., active case ﬁnding) focused on the prevention of
transmission of these highly resistant strains. Moreover, these two
Fig. 4. Allelic diversities obtained for the sample subsets genotyped with 15 (A) and 24 (B) loci MIRU-VNTR. Allelic diversities for the combined datasets or for each
individual dataset are shown. Horizontal dashed lines are used to highlight the breakpoints between low-to-intermediate and intermediate-to-high allelic diversities.
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Fig. 5. CPLP-TB database, an online
tool purposely designed to house data
on M. tuberculosis clinical isolates' ori-
ginary from the CPLP, therefore en-
abling the tracking of speciﬁc strains
across the Lusophone space. The da-
tabase features a web interface com-
posed of a main panel with six dif-
ferent page tabs and a left-sided panel
that enables users to apply ﬁlters to
data displayed on the main panel.
Data displayed on the main panel in-
clude a data-table with strain in-
formation such as drug resistance,
MIRU-VNTR alleles; diﬀerent data
plots showing enable analysis of the
selected data: a choropleth map,
which enables users to visualize the
distribution of clinical isolates; MIRU-
VNTR and Spoligotyping dendro-
grams; and, a genome-wide phyloge-
netic tree containing the isolates al-
ready subjected to WGS and annotated
with the SNP barcode nomenclature.
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clades (MtbC15-9 types: 5298-54 [Lisboa3-B] and 10,571-67 [Q1], re-
spectively) have an increasing importance in the European context as
these have been recently identiﬁed and shortlisted as MDR-TB asso-
ciated European cross-border clusters, with likely origin in Portugal,
through the detection in the United Kingdom (Q1, n= 1) and France
(Lisboa3-B, n= 1).(European Centre for Disease Prevention and
Control/WHO Regional Oﬃce for Europe, 2017).
These cluster level associations were also reﬂected by speciﬁc as-
sociations found between the spoligotyping clade and resistance type: a
higher proportion of susceptible strains, in comparison to isolates dis-
playing MDR, were found among the H1 (z-test, p < 0.001), LAM3 (z-
test, p= 0.002) and LAM9 (z-test, p= 0.024) clades; MDR isolates
were found in a higher proportion, in comparison to susceptible iso-
lates, in H3 (z-test, p < 0.001), LAM5 (z-test, p < 0.001), LAM4 (z-
test, p < 0.001) and PINI2 (z-test, p= 0.003) clades; and, XDR-TB
isolates were found in a higher proportion among LAM1 (z-test,
p < 0.001) and LAM4 (z-test, p < 0.001) isolates when compared to
MDR or susceptible isolates.
3.7. CPLP-TB: a new web-based tool for strain tracking across the CPLP
To facilitate the dissemination and inter-laboratory comparison of
the genotypic data generated in the present study we have created
CPLP-TB, an online database and web application (available at http://
cplp-tb.ﬀ.ulisboa.pt/) (Fig. 5).
This database will accommodate more data on existing strains and,
holds the potential to also accommodate more records on new strains
and/or additional genotypic markers (such as SNPs or MIRU-VNTR
hypervariable loci). Laboratories across the CPLP can also deposit data
from additional settings and/or strains thus improving the compre-
hensiveness of this new database. With this database and web appli-
cation it is also possible to track speciﬁc M. tuberculosis clones or
monitor the M. tuberculosis population structure of a given country.
The main goal of this new tool is to provide a more comprehensive
and global view of TB epidemiology in the CPLP. It holds several ad-
vantages in comparison to existing TB databases, which are intimately
related with its main mission. CPLP-TB is intended to undergo through
more rapid releases and continuous updates, including the addition of
strains from underrepresented settings, that will enable to perform or
contribute to risk assessment on speciﬁc strains at a more early stage;
submission of data will be open to other laboratories provided that the
strains deposited have been isolated within a CPLP country; it ag-
gregates phenotypic and diverse genotypic data/markers and with the
current architecture the database can be easily updated to accom-
modate additional epidemiological markers; it has been developed
speciﬁcally for CPLP countries through CPLP-based laboratories, sti-
mulating capacity development by local laboratories; and, CPLP-TB is
linked to a biobank distributed across its hosting institution and its
associated laboratories, thus enabling fundamental as well as applied
research using clinically relevant M. tuberculosis strains.
3.8. Concluding remarks
The present study constitutes the ﬁrst and largest collaborative ef-
fort to catalogue the M. tuberculosis diversity within the Lusophone
space. A total of 1447 clinical isolates with origin in ﬁve countries,
including 423 MDR-TB isolates, were analysed to provide a more global
perspective of TB in the CPLP. The population structure covered by this
analysis corroborates the high prevalence of LAM strains in most set-
tings and its dispersion argues in favour of common populational
structures, with past epidemiological links, driven by the radiation of
this speciﬁc sub-lineage out of its setting of origin, which is presently
unknown (Mokrousov et al., 2016).
Overall, this scenario argues in favour of the importance of global
TB surveillance and it is in this context that CPLP-TB database can have
a pivotal role in understanding shared transmission networks. In this
regard, 24-loci MIRU-VNTR was found to be particularly useful and
superior to the 15-loci set in analysing such a diverse dataset of clinical
isolates, as it enabled the discrimination of 15-loci MIRU-VNTR clus-
ters, which was of particular importance among cross-border clusters.
Speciﬁcally, SIT20/LAM1 strains belonging to a newly identiﬁed cluster
– CPLP-01 – emerge as the most important strains associated with more
recent transnational strain ﬂow. Most of the strains from this cluster
were identiﬁed in Angola, which, given the present epidemiological
scenario, makes it the likely origin of this particular cluster.
Nonetheless, despite known limitations of both spoligotyping and
MIRU-VNTRs, these typing methods remain the most used, easily-
available, robust, and highly aﬀordable methods – which makes them a
method of choice for TB molecular epidemiology studies, particularly
for developing countries. WGS based genomic epidemiology is not yet
widely used in such settings. Future endeavours might consist in
building new generation of databases able to establish useful links be-
tween data generated by “newer” (WGS) and “older” (spoligotyping/
MIRU-VNTRs) molecular typing methods. Such a promising develop-
ment includes a new tool named “SpoTyping” which allows in silico
determination of M. tuberculosis spoligotyping patterns with a high
accuracy from NGS reads, and subsequent lineage determinations by
interrogating the SITVIT resources (Xia et al., 2016). Such develop-
ments will allow that the vast data generated using older genotyping
methods are not denigrated and are instead useful to highlight the
distribution summaries of the meta-data corresponding to M. tubercu-
losis lineages available in CPLP-TB and SITVIT databases. As such, this
new tool, along with the several analysis and visualization tools, holds
the potential for the analysis of TB transmission in these settings with
an unprecedent resolution and can thus comprise a new framework for
the analysis of M. tuberculosis genetic diversity within the Lusophone
context and programmatic TB control.
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